Hikma Pharmaceuticals PLC (LON:HIK) Insider Purchases £3,512,000 in Stock

Key Points

• Mazen Darwazah, an insider at Hikma Pharmaceuticals PLC, purchased 200,000 shares at an average price of GBX 1,756, totaling approximately £3.51 million.
• The company's stock experienced a 1.8% decline on the following day, closing at GBX 1,719, with significant trading volume of over 3 million shares.
• Analyst ratings indicate a split outlook, with Jefferies reaffirming a "buy" rating and a price target of GBX 2,600, while JPMorgan reduced their target from GBX 2,600 to GBX 2,500.

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report) insider Mazen Darwazah acquired 200,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The stock was purchased at an average cost of GBX 1,756 ($23.59) per share, with a total value of £3,512,000 ($4,717,259.91).

Hikma Pharmaceuticals Stock Performance

Shares of LON HIK traded up GBX 46.18 ($0.62) during mid-day trading on Monday, hitting GBX 1,776.15 ($23.86). 667,189 shares of the company were exchanged, compared to its average volume of 1,038,220. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The stock has a 50 day simple moving average of GBX 2,002.76 and a 200-day simple moving average of GBX 2,046.50. Hikma Pharmaceuticals PLC has a 1-year low of GBX 1,690 ($22.70) and a 1-year high of GBX 2,360 ($31.70). The firm has a market cap of £4.93 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41.

Analyst Ratings Changes

HIK has been the subject of several research analyst reports. JPMorgan Chase & Co. decreased their price objective on Hikma Pharmaceuticals from GBX 2,600 ($34.92) to GBX 2,500 ($33.58) and set an "overweight" rating for the company in a report on Friday. Jefferies Financial Group reaffirmed a "buy" rating and set a GBX 2,600 ($34.92) price target on shares of Hikma Pharmaceuticals in a report on Thursday.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.